Business
Ludwig Enterprises Announces Agreement with Summit Bancorp to Assist with Cross Listing on the Canadian Stock Exchange
Ludwig Enterprises Announces Agreement with Summit Bancorp to Assist with Cross Listing on the Canadian Stock Exchange.
About this update from Ludwig Enterprises, Inc.
[{"type":"text","content":"SPARKS, NV / ACCESSWIRE / March 23, 2023 / Ludwig Enterprises, Inc. (OTC PINK:LUDG) (Ludwig - The Genomics Language Company ™) is pleased to announce that it has signed an agreement with Summit Bancorp of Ontario Canada to assist them in cross listing on the Canadian Stock Exchange (CSE)."Listing on the CSE expands the number of potential investors that we can attract and partnering with Summit will help Ludwig achieve this objective," says Anne Blackstone Ludwig Enterprises' CEO. "Our Ludwig subsidiary, Precision Genomics, has developed a microarray assay that measures 48 biomarkers of chronic inflammation. Our mRNA Inflammatory Index™ (patent pending) could potentially revolutionize the way cancers, COPD, diabetes and other illnesses caused by inflammation are managed."Ludwig and its subsidiary mRNAforLife, Inc. will be launching its ground-breaking nutraceutical, NuGenea™ (patent pending) in Q2 2023. NuGenea's formula includes 20 ingredients that have been proven through extensive peer reviewed research to help individuals manage inflammation, which could potentially reduce the risk for chronic illnesses.About Ludwig Enterprises, Inc.Ludwig Enterprises, Inc. is a healthcare holding company focused on cutting edge mRNA genomic technology, therapeutics and nutraceuticals. Through its subsidiary Precision Genomics it has a patent pending on the mRNA Inflammatory Index™ that measures 48 different biomarkers of inflammation. Combined with AI and deep machine learning this technology may enable healthcare professionals to identify sources of chronic inflammation and potentially prevent chronic illnesses such as diabetes, COPD, heart disease and cancer. NuGenea™, a scientifically formulated nutraceutical, supported by decades of independent research into the anti-inflammatory properties of its compounds, is manufactured by the Ludwig subsidiary mRNAforLife, Inc and its My RNA for Life™ product line of nutraceuticals.Advancements in medical technology have awarded us with cutting-edge genomic tools, unheard of even a generation ago. These genomic tools have the potential to not only detect diseases early but also to customize treatments that may improve patient outcomes and, in some cases, even extend life. Ludwig is at the forefront of this new era of medicine with their propri...